Biostage is a biotechnology company developing bioengineered organ implants based on the Company's Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants.
Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients.
Based on its pre-clinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.
January 11, 2024
RegMed Investors (RMi) Closing Bell: volatility rules
December 14, 2023
RegMed Investors (RMi) Closing Bell: “Fly me to the moon, let me play among the stars”
December 7, 2023
RegMed Investors (RMi) Closing Bell: thanks to the upside, I’m herding my portfolio to a roundup
December 6, 2023
RegMed Investors (RMi) Closing Bell: “uncle algo and his electronic dwarfs” on back of ADP report
September 26, 2023
RegMed Investors (RMi) Closing Bell: sector was at its worst just before share pricing got better
September 25, 2023
RegMed Investors (RMi) Closing Bell: Humpty Dumpty had a great fall
September 22, 2023
RegMed Investors (RMi) Closing Bell: no joy
September 21, 2023
RegMed Investors (RMi) Closing Bell: sector got scalped
September 20, 2023
RegMed Investors (RMi) Closing Bell: sector equities oscillated deeper as Fed declines to hike
September 19, 2023
RegMed Investors (RMi) Closing Bell: sector crumbles after Monday’s stumble
35 companies, 1 interpreter!
Insight, foresight and recommendation
Biostage (BSTG) - The implementation of this reverse stock split will continue CEO McGorry’s “abuse and destruction of the shareholder value due to his mismanagement, misdirection and misdeeds”. It’s all about salary and “bennies” continuance, violations of fiduciary omittance and having condoned and ignored employee – male and female harassment.” And if that isn’t enough … Is Biostage (BSTG) a Ponzi or Pyramid scheme or a combination of both …? A $300 K down payment and $4 M buys a shell from which $30 M was wasted and a $47 M deficit created …
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors